Holen Sie sich die Stockscreener-App
3.91
0.26%
0.01
Schlusskurs vom Vortag:
$3.90
Offen:
$3.9
24-Stunden-Volumen:
45,161
Relative Volume:
0.02
Marktkapitalisierung:
$27.34M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-33.65M
KGV:
-0.8787
EPS:
-4.45
Netto-Cashflow:
$-20.83M
1W Leistung:
+17.42%
1M Leistung:
+2.62%
6M Leistung:
+117.22%
1J Leistung:
+67.09%
1-Tages-Spanne:
$3.75
$3.99
1-Wochen-Bereich:
$3.27
$3.99
52-Wochen-Spanne:
$1.15
$12.46
Minerva Neurosciences Inc Stock (NERV) Company Profile
Firmenname
Minerva Neurosciences Inc
Sektor
Branche
Telefon
617-600-7373
Adresse
1500 DISTRICT AVENUE, BURLINGTON, MA
Vergleichen Sie NERV mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NERV
Minerva Neurosciences Inc
|
3.91 | 27.27M | 0 | -33.65M | -20.83M | -4.45 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.64 | 110.88B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
726.21 | 72.79B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
890.11 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.46 | 54.85B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
189.85 | 41.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Minerva Neurosciences Inc Stock (NERV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-06-08 | Bestätigt | H.C. Wainwright | Buy |
| 2020-05-14 | Eingeleitet | BTIG Research | Buy |
| 2019-10-02 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-09-25 | Eingeleitet | Chardan Capital Markets | Buy |
| 2019-09-18 | Eingeleitet | William Blair | Outperform |
| 2019-05-31 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-09-01 | Eingeleitet | Citigroup | Buy |
| 2017-03-06 | Fortgesetzt | Jefferies | Buy |
| 2016-05-12 | Fortgesetzt | Jefferies | Buy |
Alle ansehen
Minerva Neurosciences Inc Aktie (NERV) Neueste Nachrichten
Minerva Neurosciences (NERV) Price Target Increased by 12.50% to 4.59 - Nasdaq
Is Minerva Neurosciences Inc. stock a buy for dividend growth2025 EndofYear Setup & Safe Entry Zone Tips - Newser
How risky is Minerva Neurosciences Inc. (4MNA) stock compared to peersPortfolio Performance Report & Long Hold Capital Preservation Plans - Newser
How Minerva Neurosciences Inc. stock reacts to oil prices2025 Top Decliners & Technical Pattern Recognition Alerts - Newser
Minerva jumps on phase III funding, leading neuro stocks - BioWorld MedTech
Is Minerva Neurosciences Inc. stock attractive for retirement portfolios2025 Earnings Surprises & Capital Efficiency Focused Strategies - Newser
Minerva Neurosciences Stock Hits Near 2-Year High On FDA Pathway, $200M Boost — Retail Sees FDA Catalyst - MSN
Will Minerva Neurosciences Inc. (4MNA) stock boost dividends furtherSell Signal & Fast Exit and Entry Strategy Plans - Newser
Is Minerva Neurosciences Inc. (4MNA) stock cheap vs fundamentalsJuly 2025 Action & Verified Swing Trading Watchlist - Newser
Minerva Neurosciences (NERV) Stock Analysis Report | Financials & Insights - Benzinga
How Minerva Neurosciences Inc. (4MNA) stock compares with tech leadersJuly 2025 Weekly Recap & Stock Portfolio Risk Control - Newser
Market Fear: Why Minerva Neurosciences Inc 4MNA stock stays resilientJuly 2025 Outlook & Capital Efficiency Focused Ideas - BỘ NỘI VỤ
How Minerva Neurosciences Inc. stock trades during market volatilityJuly 2025 Catalysts & Free Low Drawdown Momentum Trade Ideas - BỘ NỘI VỤ
Performance Recap: What risks investors should watch in Minerva Neurosciences Inc. stock2025 Market Trends & Consistent Return Strategy Ideas - BỘ NỘI VỤ
Minerva Neurosciences Inc (NERV) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
What risks investors should watch in Minerva Neurosciences Inc. stock2025 Technical Overview & Low Risk Profit Maximizing Plans - moha.gov.vn
Why analysts upgrade Minerva Neurosciences Inc. stockJuly 2025 Opening Moves & Long Hold Capital Preservation Tips - BỘ NỘI VỤ
Contrasting Minerva Neurosciences (NASDAQ:NERV) and Madrigal Pharmaceuticals (NASDAQ:MDGL) - Defense World
What analysts say about Minerva Neurosciences Inc 4MNA stockStraddle and Strangle Trades & Superior Wealth Growth - earlytimes.in
Why Minerva Neurosciences Inc. stock appeals to analysts2025 Major Catalysts & Fast Gain Swing Trade Alerts - newser.com
Why Minerva Neurosciences Inc. (4MNA) stock attracts wealthy investorsPortfolio Growth Summary & High Conviction Buy Zone Picks - newser.com
Using Ichimoku Cloud for Minerva Neurosciences Inc. technicalsMarket Movers & Accurate Buy Signal Notifications - newser.com
Minerva Neurosciences Expands Board Amid Fundraising Effort - The Globe and Mail
Multi asset correlation models including Minerva Neurosciences Inc.July 2025 Big Picture & Weekly Top Gainers Alerts - newser.com
What to do if you’re stuck in Minerva Neurosciences Inc.Trade Signal Summary & Safe Capital Investment Plans - newser.com
Is Minerva Neurosciences Inc. stock vulnerable to regulatory risksForecast Cut & AI Forecast for Swing Trade Picks - newser.com
How buybacks impact Minerva Neurosciences Inc. stock valueEarnings Performance Report & Daily Oversold Stock Bounce Ideas - newser.com
Minerva Neurosciences appoints schizophrenia expert to board of directors By Investing.com - Investing.com Nigeria
Regression analysis insights on Minerva Neurosciences Inc. performance2025 Winners & Losers & Low Risk Entry Point Guides - newser.com
Will Minerva Neurosciences Inc. stock sustain high P E ratiosJuly 2025 Levels & Risk Controlled Daily Plans - newser.com
Is Minerva Neurosciences Inc. stock ready for a breakout2025 Technical Patterns & Long-Term Safe Investment Plans - newser.com
Minerva Neurosciences Appoints Dr. Inderjit Kaul To Board - citybiz
Minerva Neurosciences appoints Dr. Inderjit Kaul to the company's board of directors - MarketScreener
Minerva Neurosciences Appoints Dr. Inderjit Kaul To The Company’S Board Of Directors - TradingView
Minerva Neurosciences Appoints Dr. Inderjit Kaul to Board of Directors as Company Advances Clinical Development of Roluperidone for Schizophrenia Treatment - Quiver Quantitative
Minerva Neurosciences appoints schizophrenia expert to board of directors - Investing.com India
Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company’s Board of Directors - The Manila Times
Is Minerva Neurosciences Inc. stock overvalued by current metricsJuly 2025 Analyst Calls & Real-Time Volume Spike Alerts - newser.com
Will Minerva Neurosciences Inc. (4MNA) stock extend growth storyJuly 2025 Big Picture & Risk Managed Investment Entry Signals - newser.com
Visual analytics tools that track Minerva Neurosciences Inc. performanceJuly 2025 Opening Moves & Reliable Trade Execution Plans - newser.com
Automated trading signals detected on Minerva Neurosciences Inc.Weekly Market Summary & Comprehensive Market Scan Insights - newser.com
Why Minerva Neurosciences Inc. stock is seen as undervaluedMarket Trend Summary & Smart Allocation Stock Tips - newser.com
Finanzdaten der Minerva Neurosciences Inc-Aktie (NERV)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):